Employees: 2,304
Size Chongkundang (185750.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $609M, the 315th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩60,800 on 18 Nov 2026.
Performance Over six months the shares fell 26.6%, against -25.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 6.3% over the last twelve months (peer median +2.6%); the operating margin is 4.4% (peer median 4.1%).
Valuation It trades at 11.4× forward earnings against a peer median of 18.5× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points above its cost of capital (5.2% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.79T | ₩1.69T | ₩1.59T | ₩1.67T | ₩1.49T |
| Revenue growth | — | +7% | -5% | +12% | — |
| Gross profit | ₩524B | ₩517B | ₩524B | ₩655B | ₩537B |
| EBITDA | ₩125B | ₩125B | ₩139B | ₩284B | ₩144B |
| Net income | ₩78.2B | ₩77.5B | ₩109B | ₩213B | ₩81.0B |
| Free cash flow | ₩122B | -₩73.5B | ₩25.8B | ₩277B | ₩23.2B |
| Capital expenditure | ₩144B | ₩179B | ₩66.1B | ₩68.8B | ₩52.7B |
| Total debt | ₩426B | ₩368B | ₩188B | ₩220B | ₩236B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 185750.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.1% | -11.8% | 9th highest of 20 |
| 6-month return | -26.6% | -25.9% | 10th lowest of 20 |
| Distance from 52-week high | -38.0% | -43.9% | 8th highest of 20 |
| Revenue growth (TTM) | +6.3% | +2.6% | 5th highest of 15 |
| Operating margin | 4.4% | 4.1% | 7th highest of 14 |
| Forward P/E | 11.4× | 18.5× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -6.6% | 9.1% | 2nd least demanding of 10 |
| Growth delivered (Del g) | +5.4% | -1.6% | 4th highest of 10 |
| Hurdle (Req g minus delivered) | -11.9 pp | +8.1 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | +0.1 pp | -4.7 pp | 5th highest of 13 |
| EV / EBITDA | 7.0× | n/a | — |
| Net debt / EBITDA | 0.5× | -0.4× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 11.4× | -6.6% | +5.4% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | n/a | -1.0% | -17.9% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | n/a | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | n/a | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 26.8× | 20.9% | +21.9% |